Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma

Trial Profile

Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 May 2017

At a glance

  • Drugs Pazopanib (Primary) ; Trametinib (Primary)
  • Indications Cholangiocarcinoma; Ovarian cancer; Soft tissue sarcoma; Solid tumours; Thyroid cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Apr 2017 Primary endpoint (Progression free survival in patients with advanced cholangiocarcinoma) has not been met.
    • 25 Apr 2017 Results (n=25) assessing safety and efficacy of pazopanib plus trametinib in cholangiocarcinoma patients, published in the British Journal of Cancer
    • 04 Apr 2017 Efficacy results in patients with soft tissue sarcoma (n=25) published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top